1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H1, 2014

Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H1, 2014" provides data on the Peripheral T-Cell Lymphomas (PTCL) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Peripheral T-Cell Lymphomas (PTCL). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Peripheral T-Cell Lymphomas (PTCL). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Peripheral T-Cell Lymphomas (PTCL) 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Peripheral T-Cell Lymphomas (PTCL) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Peripheral T-Cell Lymphomas (PTCL) to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Peripheral T-Cell Lymphomas (PTCL) 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials 30
Prominent Drugs 32
Latest Clinical Trials News on Peripheral T-Cell Lymphomas (PTCL) 33
Aug 28, 2013: First patient dosed in part one confirmatory BelCHOP study in PTCL 33
Apr 16, 2013: Chipscreen Biosciences Announces Achievement Of Primary Endpoint In Chidamide Registrational Phase II Trial In China 33
Mar 05, 2013: TopoTarget's Belinostat Exceeds Primary Endpoint In Pivotal Trial For Patients With Peripheral T-cell Lymphoma 34
Jan 24, 2013: Topotarget's Belinostat Demonstrates Favorable Safety Profile In Phase II Peripheral T-cell Lymphoma Study 34
Jan 08, 2013: TG Therapeutics Initiates First-in-human Phase I Clinical Trial For TGR-1202 In Patients With Hematologic Malignancies 35
Clinical Trial Profiles 36
Clinical Trial Overview of Top Companies 36
Celgene Corporation 36
Clinical Trial Overview of Celgene Corporation 36
Spectrum Pharmaceuticals, Inc. 37
Clinical Trial Overview of Spectrum Pharmaceuticals, Inc. 37
Kirin Holdings Company, Limited 38
Clinical Trial Overview of Kirin Holdings Company, Limited 38
Eisai Co., Ltd. 39
Clinical Trial Overview of Eisai Co., Ltd. 39
Topotarget A/S 40
Clinical Trial Overview of Topotarget A/S 40
Takeda Pharmaceutical Company Limited 41
Clinical Trial Overview of Takeda Pharmaceutical Company Limited 41
Bayer AG 42
Clinical Trial Overview of Bayer AG 42
Solasia Pharma K.K. 43
Clinical Trial Overview of Solasia Pharma K.K. 43
Mundipharma International Limited 44
Clinical Trial Overview of Mundipharma International Limited 44
AbbVie Inc. 45
Clinical Trial Overview of AbbVie Inc. 45
Clinical Trial Overview of Top Institutes / Government 46
National Cancer Institute 46
Clinical Trial Overview of National Cancer Institute 46
Fred Hutchinson Cancer Research Center 48
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 48
The University of Texas M. D. Anderson Cancer Center 50
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 50
University of Nebraska 51
Clinical Trial Overview of University of Nebraska 51
Mayo Clinic 52
Clinical Trial Overview of Mayo Clinic 52
Stanford University 53
Clinical Trial Overview of Stanford University 53
University of Washington 54
Clinical Trial Overview of University of Washington 54
Case Comprehensive Cancer Center 55
Clinical Trial Overview of Case Comprehensive Cancer Center 55
University of Gottingen 56
Clinical Trial Overview of University of Gottingen 56
University of California, San Francisco 57
Clinical Trial Overview of University of California, San Francisco 57
Five Key Clinical Profiles 58
Appendix 118
Abbreviations 118
Definitions 118
Research Methodology 119
Secondary Research 119
About GlobalData 120
Contact Us 120
Disclaimer 120
Source 121

List of Tables
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials by Region, 2014* 7
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014* 14
Proportion of Peripheral T-Cell Lymphomas (PTCL) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Peripheral T-Cell Lymphomas (PTCL) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Suspended Clinical Trials, 2014* 25
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 31
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 36
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Spectrum Pharmaceuticals, Inc., 2014* 37
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Kirin Holdings Company, Limited, 2014* 38
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Eisai Co., Ltd., 2014* 39
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Topotarget A/S, 2014* 40
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014* 41
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Bayer AG, 2014* 42
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Solasia Pharma K.K., 2014* 43
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mundipharma International Limited, 2014* 44
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 45
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 46
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 48
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 50
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Nebraska, 2014* 51
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014* 52
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 53
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Washington, 2014* 54
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 55
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Gottingen, 2014* 56
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 57

List of Figures
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014* 14
Proportion of Peripheral T-Cell Lymphomas (PTCL) to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Peripheral T-Cell Lymphomas (PTCL) to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Peripheral T-Cell Lymphomas (PTCL) Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Peripheral T-Cell Lymphomas (PTCL) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 32
GlobalData Methodology 119

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Hodgkin's Lymphoma Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Hodgkin’s Lymphoma in 17 Major Markets Hodgkin’s Lymphoma (HL) is a cancer (also known as Hodgkin Disease, Hodgkin Lymphoma o ...

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market  Forecast-2023

Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

Small lymphocytic lymphoma- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Small lymphocytic lymphoma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.